The false positive rate of NIPS is 100x lower than serum screening in patients in the general obstetric population.1
positive predictive value
Positive predictive value (PPV) is 20-fold higher than in standard serum screening.1
Professional societies such as ACOG and ACMG endorse and/or recognize NIPS as a screening option for all pregnant women.2,3
Excellent test performance which helps simplify practice workflow.
- Industry-leading test failure rate of 0.1%.4,5
- Fewer redraws, fewer unnecessary invasive procedures, shorter overall turnaround time, and decreased anxiety for your patients6,7
Personalized expert analysis of your patients’ samples through:
- Custom algorithms and bioinformatics combined with expert manual review
- Maximized test performance for each sample based on its own individual metrics
One test for all your patients
- Including pregnancies with an ovum donor, patients with a high body-mass Index (BMI) and twin pregnancies
A primary focus on common aneuploidies, as recommended by societal guidelines,1 with options for additional testing
Clear risk assessment:
Clarity of your patient’s true risk with individualized positive predictive values (PPV) and residual risk estimates to help inform next steps
We provide resources to help you educate your patients about Myriad products.
We offer a comprehensive program to make genetic products accessible for more of your patients.
We deliver screening and testing results effectively and thoroughly so you can focus on care plans.
We provide consults from genetic counselors tailored to help your patient understand their results.
The Myriad Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as Down syndrome.
cfDNA screening has been shown to be superior to methods that use maternal age, ultrasound, and serum screening. This results in a lower false-positive rate and false-negative rate.2
The Prequel Prenatal Screen can be ordered with the ForesightTM Carrier Screen and offered to all women, including those with high BMI, an ovum donor or a twin pregnancy.
- Monosomy X (Turner syndrome)
- XXY (Klinefelter syndrome)
- Trisomy X (Triple X syndrome)
- XYY (Jacob syndrome)
Microdeletion and sex chromosome screening are optional.
While looking at sex chromosomes, we can report the predicted fetal sex.
Common aneuploidies: Trisomy 21, Trisomy 18, Trisomy 13.
Optional analysis of sex chromosomes and microdeletions.
Who to screen
All pregnant women
When to screen
As early as 10 weeks into pregnancy
One tube of blood
Approximately 1 week
Lacey, 37 (pictured with fiancé Sejin)
Myriad Prequel Prenatal Screen patient, expecting her first baby girl
- Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597.
- Practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):e123–37.
- Noninvasive Prenatal Screening for Fetal Aneuploidy, 2016 Update: A Position Statement of the American College of Medical Genetics and Genomics. Obstetrical and Gynecological Survey. 2017 Jan 1;72(1):6-8.
- Taneja et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85000 cases†. Prenatal Diagnosis 2016, 36, 1–7.
- Data on file
- Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014:370(9):799-808.
- Artieri, C. G., Haverty, C., Evans, E. A., Goldberg, J. D., Haque, I. S., Yaron, Y., and Muzzey, D. (2017) Noninvasive Prenatal Screening at Low Fetal Fraction: Comparing Whole-Genome Sequencing and Single-Nucleotide Polymorphism Methods. Prenat Diagn, doi: 10.1002/pd.503
- Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119(5):890-901.
- Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2017;50:302-14.
- Gravholt CH, Juul S, Naeraa RW, Hansen J. Prenatal and postnatal prevalence of Turner's syndrome : a registry study. BMJ. 1996;312:16-21.
- Illumina, Inc. Analytical Validation of the verifi® prenatal test: Enhanced Test Performance for Detecting Trisomies 21, 18, and 13 and the Option for Classification of Sex Chromosome Status. 2012.
- Liao H, Liu S, Wang H. Performance of non-invasive prenatal screening for fetal aneuploidy in twin pregnancies: a meta-analysis. Prenat Diagn. 2017;37: 874-882.
- Rodis JF, Egan JF, Craffey A, Ciarleglio L, Greenstein RM, Scorza WE. Calculated risk of chromosomal abnormalities in twin gestations. Obstet Gynecol. 1990;76: 1037-1041.
- Simpson LL. Twin-twin transfusion syndrome. Am J Obstet Gynecol. Elsevier; 2013;208: 3-18.
- Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70.
- Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH. Maternal age and gestation age-specific risks for chromosomal defects. Fetal Diag Ther 1995;10:356-67.